Simon Burton

Dr Ben Swift has been awarded a Horizon award by AMI for his ground-breaking work developing a phage-based diagnostic for tuberculosis.

Grant of a patent has been awarded to PBD Biotech for its Actiphage diagnostic for incipient tuberculosis in South Africa, this complements the regional West Africa patent gained earlier this year.

The Translational Microbiology Prize is awarded to an individual who has demonstrated an outstanding contribution to translational microbiology.

PBD Biotech has been working closely with the R2D2 TB Network to set up the trial protocol for its Actiphage® tuberculosis diagnostic, and the first test kit is being dispatched.

PBD Biotech is one of the finalists selected to participate in the 42plus1 pitch event at DxPx EU in Munich, Germany on the 5th October 2023. This follows our participation in DxPx US.

Conventional phase 3 trials do not provide key information about the overall effect of introducing a new tuberculosis vaccine programme and so are missing crucial information for policy makers, argue experts in a personal view in Lancet Microbe.

PBD Biotech is one of the companies represented at a parliamentary reception organised by the British In Vitro Diagnostics Association (BIVDA)

The Inv€$tival Showcase in Old Billingsgate, London, is part of Europe’s biggest healthcare investment week. It will feature Actiphage TB, a groundbreaking diagnostic for tuberculosis.

PBD Biotech, developers of Actiphage® TB, a ground-breaking phage-based diagnostic for laboratory tuberculosis testing, has today announced it has secured a US patent grant for TB diagnostic kit.

Actiphage TB is to enter its third clinical trial, which is aimed at validating its utility as a tuberculosis diagnostic. The phage-based diagnostic has potential for detecting TB progression.

The bacteriophage-based diagnostic may play vital role in detecting TB progression

Without treatment 1 in 10 people with latent TB will progress to active TB but how can they be identified?